How should persistent unilateral hip weakness following a recent parvovirus infection be evaluated and managed?

Unilateral Hip Weakness Following Parvovirus Infection

This presentation most likely represents parvovirus B19-associated mononeuropathy multiplex affecting the hip region, and you should immediately obtain serologic testing (IgM/IgG) plus PCR for parvovirus B19 DNA, perform EMG/NCS to characterize the neuropathy pattern, and strongly consider early IVIG therapy (2 g/kg over 2-5 days) if acute infection is confirmed.

Diagnostic Approach

Initial Testing Priority

The unilateral hip weakness following parvovirus infection suggests a neurologic rather than arthritic etiology. Parvovirus B19 can cause mononeuropathy multiplex (MM) with characteristic features 1:

• Sensory symptoms typically precede motor weakness - look for numbness or paresthesias that started in the hand or distal limb before hip weakness developed
• Asymmetric, multifocal nerve involvement progressing in a subacute pattern over days to weeks
• May be accompanied by limited purpuric rash without systemic vasculitis

Specific Diagnostic Tests

Confirm active parvovirus infection:

• IgM and IgG serology (though serology may be unreliable in immunocompromised patients) 2
• PCR for parvovirus B19 DNA - essential if immunosuppressed or if serology is equivocal 3
• High viral load correlates with symptomatic disease 3

Characterize the neuropathy:

• EMG/nerve conduction studies showing multifocal asymmetric sensory and motor axonal loss confirms MM 1
• Consider nerve biopsy if diagnosis remains unclear - may show lymphocytic perivascular infiltrate without necrotizing vasculitis 1

Critical Pitfall to Avoid

Do not mistake this for Lyme disease or early rheumatoid arthritis - parvovirus B19 arthralgia/arthritis can mimic these conditions and lead to inappropriate antibiotic or DMARD therapy 4, 5. The unilateral hip weakness pattern with neurologic findings distinguishes this from typical parvovirus polyarthritis, which presents as symmetric polyarthralgia predominantly affecting small joints 5, 6.

Treatment Algorithm

If acute parvovirus B19 infection confirmed with MM:

1. Administer IVIG 2 g/kg divided over 2-5 days 1, 3

   • Avoid daily doses >1 g/kg due to higher toxicity risk 3
   • This is the standard treatment for parvovirus-associated neurologic complications

2. Reduce immunosuppression if applicable - check if patient is on methotrexate, biologics, or other immunosuppressants that may perpetuate infection 7

3. Monitor viral load with PCR - persistent low-level DNAemia after treatment may not be clinically significant 3

Expected Outcomes and Follow-up

Long-term prognosis is generally good with IVIG treatment, though expect:

• Incomplete sensory recovery is common 1
• Functional disability may persist in some patients 1
• Clinical remission typically occurs within 34±47 days in most cases 5

Monitor for progression: While most parvovirus manifestations are self-limited 6, approximately 15% may develop persistent symptoms requiring corticosteroids, and a small minority (~10%) may need DMARD escalation if symptoms persist beyond 3 months 5, 6.

Imaging Considerations

If hip pain is prominent or diagnosis remains uncertain after neurologic workup, obtain MRI of the hip without contrast 8 to exclude:

• Soft tissue abnormalities (bursitis, tendinopathy)
• Occult fracture or osteonecrosis
• Intra-articular pathology

However, the unilateral weakness pattern strongly suggests a neurologic rather than structural hip problem, making EMG/NCS the priority over imaging.